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Endotoxin (LPS) can evoke a shock state in mammals, characterized by fever,
hypotension, diarrhea, leukopenia, disseminated intravascular coagulation, and
multiple end-organ damage. This syndrome does not result from the action of
the LPS per se; on the contrary, endotoxin evokes the production of toxic
endogenous mediators, which in turn cause widespread tissue injury (1).
The most prominent mediator of the lethal effect of LPS appears to be
cachectin (tumor necrosis factor; TNF) (2, 3), a macrophage hormone produced
in milligram quantities by animals treated with LPS (4, 5). Cachectin binds to
receptors widely distributed throughout the body (4), causing severe metabolic
acidosis, a biphasic change in plasma glucose levels, and inflammatory lesions in
the lungs, gastrointestinal tract, kidneys, adrenals, and pancreas (6), often with
fatal consequences.
Recently (7), we showed that endotoxin-resistant (C3H/HeJ) mouse macro-
phages, bearing the lpsd mutation, fail to produce cachectin in significant quan-
tities in response to LPS, as a result of a dual biosynthetic lesion. First, the cells
fail to exhibit a normal transcriptional response to low concentrations of endo-
toxin, and second, the cachectin mRNA that is produced is not translated to
protein. Probably as a result of these defects, the mice are capable ofsurviving
the administration of large amounts of LPS.
IFN-y, like LPS, is capable of activating human monocytes/macrophages (8).
Increased phagocytic activity and increased generation ofH202 may be observed
in these cells after addition of IFN-y. We wished to determine whether IFN-y
was also capableofeliciting cachectin production, andifso, whether macrophages
obtained from the endotoxin-resistant C3H/HeJ mouse would respond to this
mediator.
In the present report, we show that IFN-y by itself is not capable ofstimulating
cachectin production by isolated mouse peritoneal macrophages. However, IFN-
y appears to augment cachectin biosynthesis in response to LPS, acting at both
transcriptional and posttranscriptional levels. It can also overcome the blockade
imposed by the lpsd mutation in C3H/HeJ (endotoxin-resistant) macrophages
and permit the biosynthesis ofcachectin in response to LPS.
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FIGURE 1 . Production of cachectin (Cach) by peritoneal macrophages obtained from
C3H/HeN (N) and C3H/HeJ (J) mice. Cells were treated with (+) or without (-) endotoxin
(L) or IFN-y (y), each at a concentration of 1 ug/ml . Medium was harvested after 16 h and
analyzed by immunoconcentration and immunoblotting .
Materials and Methods
Recombinant mouse IFN--y was obtained from Genentech Corporation (South San
Francisco, CA) . E. coli (strain 0127:13$) LPS was obtained from Difco Laboratories
(Detroit, MI) .
Female C3H/HeJ mice (20-g size) were obtained from The Jackson Laboratory (Bar
Harbor, ME), and female C3H/HeN mice (20-g size) were obtained from the Charles
River Breeding Co . (Wilmington, MA) . Animals were kept in the Rockefeller University
Laboratory Research Center before use in these experiments . Mice were injected i.p . with
3 ml of sterile Brewer's thioglycollate medium . 3-5 d later, macrophages were harvested
by peritoneal lavage using HBSS, sedimented at 1,000 g, resuspended in RPMI 1640
medium containing 10% FCS, and plated at confluent density in 24-well Linbro plates
(Flow Laboratories, Inc ., McLean, VA). After 1 h, nonadherent cells were washed away
with serum-free RPM[ 1640 medium, and adherent monolayers were covered with the
same medium . Cells were then induced with varying concentrations of IFN--y and/or LPS
at the times noted .
Medium was harvested from monocyte or macrophage cultures after incubation with
the above mediators, and cachectin was detected by means of an immunoconcentra-
tion/immunoblot assay described previously (7) . Cell monolayers were lysed, and total
cellular RNA was isolated in order to quantitate cachectin mRNA . To prepare RNA for
electrophoresis, a standard procedure involving ribonuclease inactivation by guanidinium
isothiocyanate and selective precipitation of RNA by 3 M LiCl (9) was used. After
electrophoresis of the RNA from each monolayer, cachectin mRNA was measured by
blot hybridization using a nick-translated probe complementary to mouse cachectin
mRNA (10), or in some instances, using a synthetic RNA probe (11).
Results
As described previously (7), both the mature hormone and processing inter-
mediates are readily visualized on immunoblots ofmacrophage medium (Fig. 1) .
Macrophages obtained from C3H/HeN (endotoxin-sensitive) mice produce copi-
ous quantities of cachectin in response to LPS, whether or not they have been
treated with IFN-y . Moreover, IFN-y is incapable of eliciting cachectin produc-
tion in these cells in the absence of LPS .
C3H/HeJ (endotoxin-resistant) mouse macrophages produce little or no ca-
chectin in response to LPS, at 1 ,ug/ml, or in response to IFN--y alone ; however,
normal quantities of cachectin are produced if the cells are treated with IFN--y
before LPS induction (Fig . 1) . Thus, the effect of the lpsd mutation is mitigated
by exposure to IFN-y . As seen in Fig . 2a, relatively high concentrations o£ LPS
are required to induce cachectin secretion in IFN-y-treated C3H/HeJ macro-
phages . Very little cachectin is produced by C3H/HeJ cells exposed to LPS at a
concentration below 1 gg/ml .
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FIGURE 2 .
￿
Inductionof cachectinmRNA and protein biosynthesis in C3H/HeJ macrophages
treated with varying concentrations of endotoxin, with or without IFN-y . a and b, immuno-
reactive cachectin (Cach) production in cells exposed to LPS at the indicated concentrations
(wg/ml) after treatment (a and b, respectively) with or without IFN--y . cand d, cachectinmRNA
production by cells exposed to LPS at the indicated concentrations after treatment (c and d,
respectively) with or without IFN--y .
FIGURE 3 .
￿
a, production of cachectin (Cach) by C3H/HeJ macrophages treated with 1 wg/ml
LPS in the presence of varying concentrations (kg/ml) of recombinant mouse IFN--y . b,
production of cachectin by C3H/HeJ macrophages treated with 1 lag/ml LPS, with 1 ug/ml
IFN-y added at varying times relative to the addition of LPS . In both instances, medium was
harvested 16 h after the addition of LPS, and cachectin concentration estimated by immuno-
concentration andimmunoblotting.
treated C3H/HeJ macrophages (Fig . 2c) . In addition, it appears to facilitate
endotoxin-induced cachectin biosynthesis at a posttranscriptional level, since cells
containing high levels of cachectin mRNA (Fig . 2d) (for example, those treated
with 1 jug/ml of LPS) fail to produce normal quantities of immunoreactive
protein in the absence of IFN-y (Fig . 2 b) .
IFN-y was added to C3H/HeJ macrophages over a wide range of concentra-
tions to determine whether the observed effect occurred at a high dilution,
consistent with a receptor-mediated phenomenon (Fig . 3 a) . Full activation of
endotoxin-induced cachectin biosynthesis was observed in the presence of 1
ng/ml IFN-y . It was also noted (Fig . 3b) that cells treated with IFN-y before
addition of LPS produced greater quantities of cachectin than cells treated with
both agents simultaneously, or cells treated with LPS followed by IFN-y.1794
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Discussion
Cachectin is a highly toxic protein that appears to act as the primary mediator
of LPS-induced shock (3, 6, 7, 12). Systemic release of cachectin leads, among
other things, to fever, hypotension, metabolic acidosis, and inflammatory lesions
of the lungs, bowel, adrenals, and kidneys. As such, cachectin biosynthesis must
be strictly regulated (7). While cachectin mRNA synthesis occurs constitutively,
and is augmented by a number of agents, the protein is not translated under
normal circumstances. Endotoxin has been shown (7) to greatly increase the rate
of cachectin gene transcription, and to allow the posttranscriptional phase of
biosynthesis to proceed. In the present report, we have studied the effect of IFN-
y on cachectin expression at both levels .
A variety of chemical and biological agents, including LPS and IFN-'y, activate
macrophages, as assessed by morphologic criteria, secretion of plasminogen
activator, phagocytosis of opsonized erythrocytes, suppression of 5'-nucleotidase
activity, production of oxidative metabolites, and destruction of intracellular
pathogens (13, 14). However, with respect to the production of cachectin,
macrophage activation induced by IFN-y differs from activation induced by
LPS. IFN-y appears to prime murine peritoneal macrophages, allowing them to
produce cachectin in response to LPS. However, IFN-y does notevoke cachectin
production by itself.
This permissive effect has been noticed by other investigators. Pace, et al. (15,
16) reported that IFN-y allowed the expression of tumoricidal activity by mouse
macrophages after LPS stimulation. More recently, Nedwin, et al. (17) showed
that IFN-y augmented the LPS-induced production of TNF activity by human
peripheral blood monocytes. Here, we have demonstrated that the permissive
effect of IFN-y involves both transcriptional and posttranscriptional phases (7)
of the LPS-induced response.
In macrophages obtained from the C3H/HeJ mouse, cachectin biosynthesis is
defective because a proximal lesion prevents both LPS-induced cachectin gene
transcription andcachectin mRNA translation . IFN-yappears to partially correct
the lpsd phenotype, allowing normal expression of cachectin by these cells in
response to relatively low concentrations LPS.
Vogel and her associates (18) have reported that macrophages derived from
C3H/HeJ mice fail to develop a normal capacity for Fc receptor-mediated
phagocytosis in vitro. This defect can be corrected by treatment with conditioned
medium obtained from Con A-stimulated lymphocytes (19), or by direct treat-
ment with recombinant interferons (20).
It has been suggested (21) that the abnormality manifested by C3H/HeJ
macrophages might reflect a differentiation defect, consequent to insufficient
production of interferon, since anti-interferon a/,Q prevented the normal devel-
opment of Fc receptor-mediated phagocytosis in cultures of C3H/HeN cells. As
mentioned above, it has been noted (17) that human peripheral blood monocytes
produce far larger quantities of TNF in response to LPS if first primed with
IFN-y. Our own unpublished studies confirm this observation, and suggest that
the enhancement of monocyte cachectin biosynthesis results from augmented
cachectin gene transcription and cachectin mRNA translation. The phenotypic
resemblance of human peripheral blood monocytes and C3H/HeJ macrophages(with respect to cachectin production) may be taken to imply that the defect
manifested by lpsd-type cells is, indeed, of a developmental nature.
The mechanism by which IFN-7 augments the normal transcriptional and
posttranscriptional responses to endotoxin peripheral blood monocytes and in
C3H/HeJ macrophages (thus mitigating the effect of the lpsd allele) remains
unclear. In view of the fact that pretreatment of the macrophages with IFN-y
maximizes cachectin production in response to endotoxin, it may be that protein
synthesis is required for IFN-'Y to exert its effect.
The identification of IFN-'Y as a modulator of cachectin production in response
to LPS may be of assistance in defining the molecular events that occur after the
macrophage has been exposed to this agent. Moreover, this effect of IFN-'Y may
have significant consequences in vivo. IFN-'Y may act to increase the sensitivity
of recipient animals to endotoxin, by facilitating cachectin production in response
to LPS. Indeed, it is possible that the priming effect exerted by facultative
intracellular bacterial infection may depend upon IFN-y production, or the
elaboration of a related cytokine.
Summary
IFN-y permits the endotoxin-induced production of cachectin by C3H/HeJ
(endotoxin resistant) macrophages, apparently by facilitating endotoxin-induced
cachectin biosynthesis at both transcriptional and posttranscriptional levels. IFN-
y cannot induce cachectin biosynthesis by itself, nor does it markedly enhance
cachectin production by endotoxin-induced peritoneal macrophages obtained
from endotoxin-responsive mice. Elucidation of the precise mechanism through
which IFN-y influences cachectin biosynthesis may permit abetter understanding
of themolecularevents that follow endotoxin-induced activation of macrophages.
Moreover, the permissive effect of IFN-y on cachectin biosynthesis might elicit
enhanced endotoxin sensitivity in vivo .
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